Objectives: Current British guidelines advocate the use of risk prediction scores such as Thoracoscore to estimate mortality prior to radical surgery for non-small cell lung cancer (NSCLC). A recent publication used the National Lung Cancer Audit (NLCA) to produce a score to predict 90 day mortality (NLCA score). The aim of this study is to validate the NLCA score, and compare its performance with Thoracoscore. Materials and methods: We performed an internal validation using 2858 surgical patients from NLCA and an external validation using 3191 surgical patients from the Danish Lung Cancer Registry (DLCR). We calculated the proportion that died within 90 days of surgery. The discriminatory power of both scores was assessed by a receiver...
OBJECTIVE: To investigate opportunities to reduce lung cancer mortality after diagnosis of localised...
ObjectiveThoracoscore is the first multivariate model for the prediction of in-hospital mortality af...
BACKGROUND: Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases,...
Objectives: Current British guidelines advocate the use of risk prediction scores such as Thoracosco...
The Thoracoscore mortality risk model has been incorporated into the British Thoracic Society guidel...
International audienceOBJECTIVE: This study was undertaken to determine factors associated with in-h...
Objective Surgery is the first choice of treatment for localised non small cell lung cancer (NSCLC) ...
OBJECTIVES: Thoracoscore is incorporated in the new British Thoracic Society and National Institute ...
ObjectiveThis study was undertaken to determine factors associated with in-hospital mortality among ...
OBJECTIVE:Overall survival (OS) for advanced stage (IIIA-IV) non-small cell lung cancer (NSCLC) is h...
Background: Thoracoscore and the European Society Objective Score (ESOS.01) are two scoring systems ...
BACKGROUND: Postoperative mortality (POM) after surgery for lung cancer has been proposed as a perfo...
ObjectiveWe sought to develop risk-adjusted morbidity and mortality models to compare the performanc...
Background: In comparison with other European and North American countries, England has poor surviva...
Background: Increased age of cancer patients is not an absolute contraindication to pulmonary resect...
OBJECTIVE: To investigate opportunities to reduce lung cancer mortality after diagnosis of localised...
ObjectiveThoracoscore is the first multivariate model for the prediction of in-hospital mortality af...
BACKGROUND: Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases,...
Objectives: Current British guidelines advocate the use of risk prediction scores such as Thoracosco...
The Thoracoscore mortality risk model has been incorporated into the British Thoracic Society guidel...
International audienceOBJECTIVE: This study was undertaken to determine factors associated with in-h...
Objective Surgery is the first choice of treatment for localised non small cell lung cancer (NSCLC) ...
OBJECTIVES: Thoracoscore is incorporated in the new British Thoracic Society and National Institute ...
ObjectiveThis study was undertaken to determine factors associated with in-hospital mortality among ...
OBJECTIVE:Overall survival (OS) for advanced stage (IIIA-IV) non-small cell lung cancer (NSCLC) is h...
Background: Thoracoscore and the European Society Objective Score (ESOS.01) are two scoring systems ...
BACKGROUND: Postoperative mortality (POM) after surgery for lung cancer has been proposed as a perfo...
ObjectiveWe sought to develop risk-adjusted morbidity and mortality models to compare the performanc...
Background: In comparison with other European and North American countries, England has poor surviva...
Background: Increased age of cancer patients is not an absolute contraindication to pulmonary resect...
OBJECTIVE: To investigate opportunities to reduce lung cancer mortality after diagnosis of localised...
ObjectiveThoracoscore is the first multivariate model for the prediction of in-hospital mortality af...
BACKGROUND: Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases,...